X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pravastatin (1033) 1033
humans (876) 876
pharmacology & pharmacy (652) 652
male (592) 592
index medicus (481) 481
female (416) 416
simvastatin (403) 403
statins (392) 392
animals (339) 339
pharmacokinetics (315) 315
atorvastatin (309) 309
middle aged (284) 284
adult (277) 277
drug interactions (264) 264
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (216) 216
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (210) 210
cholesterol (209) 209
pravastatin - pharmacokinetics (205) 205
aged (197) 197
lovastatin (186) 186
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (182) 182
hypercholesterolemia (173) 173
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (171) 171
rats (164) 164
pravastatin - pharmacology (163) 163
antilipemic agents (156) 156
coa reductase inhibitors (146) 146
hypercholesterolemia - drug therapy (140) 140
rosuvastatin (140) 140
fluvastatin (136) 136
pravastatin - therapeutic use (135) 135
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (123) 123
research (122) 122
analysis (118) 118
dose-response relationship, drug (112) 112
metabolism (112) 112
atorvastatin calcium (111) 111
organic anion transporters - genetics (111) 111
prevention (109) 109
cardiac & cardiovascular systems (107) 107
solute carrier organic anion transporter family member 1b1 (106) 106
anticholesteremic agents - therapeutic use (105) 105
treatment outcome (105) 105
area under curve (104) 104
cholesterol, ldl - blood (102) 102
coronary-heart-disease (101) 101
lipids (101) 101
safety (101) 101
liver - metabolism (100) 100
risk factors (99) 99
rhabdomyolysis (97) 97
rosuvastatin calcium (97) 97
anticholesteremic agents - pharmacokinetics (96) 96
efficacy (96) 96
drugs (90) 90
pravastatin - administration & dosage (90) 90
drug therapy (86) 86
statin (86) 86
therapy (85) 85
cholesterol - blood (84) 84
pharmacology/toxicology (82) 82
hmg-coa reductase (80) 80
mice (78) 78
pharmacogenetics (77) 77
cross-over studies (76) 76
risk (75) 75
atherosclerosis (74) 74
time factors (74) 74
health aspects (72) 72
rats, sprague-dawley (72) 72
drug therapy, combination (71) 71
medicine & public health (71) 71
organic anion transporters - metabolism (71) 71
expression (69) 69
anticholesteremic agents - pharmacology (67) 67
medicine, general & internal (66) 66
pravastatin - blood (66) 66
simvastatin - pharmacology (66) 66
anticholesteremic agents - adverse effects (65) 65
biochemistry & molecular biology (65) 65
double-blind method (65) 65
disease (64) 64
disposition (64) 64
hydroxymethylglutaryl-coa reductase inhibitors - blood (64) 64
liver (64) 64
in-vitro (63) 63
coenzyme-a reductase (62) 62
dosage and administration (62) 62
hydroxymethylglutaryl-coa reductase inhibitors (62) 62
myocardial-infarction (62) 62
simvastatin - therapeutic use (62) 62
administration, oral (61) 61
drug-interactions (61) 61
hepatic-uptake (61) 61
internal medicine (61) 61
slco1b1 (61) 61
pharmacology (60) 60
anticholesteremic agents - administration & dosage (59) 59
p-glycoprotein (58) 58
pravastatin - adverse effects (58) 58
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1359) 1359
Japanese (7) 7
Chinese (5) 5
French (5) 5
Spanish (4) 4
German (3) 3
Danish (1) 1
Italian (1) 1
Korean (1) 1
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 2004, Volume 94, Issue 9, pp. 1140 - 1146
Three-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) are first-line treatments for hypercholesterolemia. Although exceedingly well... 
CLARITHROMYCIN | INDUCED RHABDOMYOLYSIS | LOVASTATIN | CARDIAC & CARDIOVASCULAR SYSTEMS | CONCOMITANT USE | ERYTHROMYCIN | FATAL RHABDOMYOLYSIS | ITRACONAZOLE | ROSUVASTATIN | DRUG-INTERACTION | CYCLOSPORINE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Pyrroles - pharmacokinetics | Cytochrome P-450 Enzyme Inhibitors | Cytochrome P-450 Enzyme System - administration & dosage | Area Under Curve | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Mibefradil - pharmacokinetics | Male | Protein Synthesis Inhibitors - administration & dosage | Verapamil - administration & dosage | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Antiprotozoal Agents - pharmacokinetics | Drug Interactions | Itraconazole - pharmacokinetics | Pyrroles - administration & dosage | Clarithromycin - pharmacokinetics | Mibefradil - administration & dosage | Clarithromycin - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Itraconazole - administration & dosage | Drug Therapy, Combination | Double-Blind Method | Simvastatin - administration & dosage | Verapamil - pharmacokinetics | Biomarkers - blood | Simvastatin - pharmacokinetics | Protein Synthesis Inhibitors - pharmacokinetics | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Adolescent | Antiprotozoal Agents - administration & dosage | Calcium Channel Blockers - administration & dosage | Creatine Kinase - drug effects | Calcium Channel Blockers - pharmacokinetics | Pravastatin - pharmacokinetics
Journal Article
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2009, Volume 54, Issue 17, pp. 1609 - 1616
Objectives We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects. Background Statin-induced side effects can... 
Cardiovascular | Internal Medicine | clinical trial | hydroxymethylglutaryl-CoA reductase inhibitors | adverse events | single nucleotide polymorphisms | myopathy | pharmacogenetics | TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | ACID | SAFETY | SLCO1B1 POLYMORPHISM | INDUCED MYOPATHY | ATORVASTATIN | PHARMACOKINETICS | DISEASE | PRAVASTATIN | LACTONE | Haplotypes | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Male | Heptanoic Acids - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Pravastatin - adverse effects | Pyrroles - adverse effects | Female | Muscular Diseases - chemically induced | Hypolipidemic Agents - adverse effects | Creatine Kinase - blood | Simvastatin - pharmacokinetics | Muscular Diseases - blood | Atorvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Aged | Polymorphism, Single Nucleotide | Hypolipidemic Agents - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Pravastatin - pharmacokinetics | Enzymes | Hypotheses | Acids | Mortality | Cardiovascular disease | Muscle pain | Drug therapy | Statins | Cholesterol | Index Medicus | Abridged Index Medicus | muscular diseases | hydroxymethylglutaryl-CoA Reductase Inhibitors
Journal Article
Journal Article
Journal Article
Pharmacogenomics Journal, ISSN 1470-269X, 02/2010, Volume 10, Issue 1, pp. 1 - 11
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are well established in the treatment of hypercholesterolaemia and the prevention of... 
SLCO1B1 | Statin | Transporter | Cholesterol | Myopathy | Polymorphism | REDUCTASE INHIBITORS | INTERINDIVIDUAL DIFFERENCES | myopathy | DRUG-INTERACTIONS | MULTIPLE-DOSE PRAVASTATIN | polymorphism | C SLC21A6 | LIPID-LOWERING EFFICACY | ANION TRANSPORTING POLYPEPTIDE | ABCB1 HAPLOTYPES | statin | transporter | GENETICS & HEREDITY | FUNCTIONAL-ANALYSIS | cholesterol | PHARMACOLOGY & PHARMACY | SINGLE NUCLEOTIDE POLYMORPHISMS | Haplotypes | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Heptanoic Acids - pharmacokinetics | Humans | Liver | Hepatocytes - metabolism | Hypercholesterolemia - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Pharmacogenetics | Gene Frequency | Rosuvastatin Calcium | Simvastatin - pharmacokinetics | Anticholesteremic Agents - adverse effects | Sulfonamides - pharmacokinetics | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Asian Continental Ancestry Group | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | HeLa Cells | Solute Carrier Organic Anion Transporter Family Member 1b1 | Pravastatin - pharmacokinetics | Research | Health aspects | Coronary heart disease | Genetic polymorphisms | Statins | Risk factors
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 168 - 176
This study investigated the role of a multispecific organic anion transporter, Oatp1a4/ Slco1a4 , in drug transport across the blood-brain barrier. In vitro... 
LOCALIZATION | INVOLVEMENT | POLYPEPTIDE-2 | PENETRATION | PHARMACOLOGY & PHARMACY | RAT-BRAIN | OATP2 | BCRP/ABCG2 | 17-BETA-ESTRADIOL-D-17-BETA-GLUCURONIDE | CANCER RESISTANCE PROTEIN | P-GLYCOPROTEIN | Fluorobenzenes - pharmacokinetics | Gene Expression - genetics | Pyrimidines - blood | Humans | Ion Pumps - genetics | Fluorobenzenes - administration & dosage | Quinolines - administration & dosage | Pyrimidines - metabolism | Brain - metabolism | Quinolines - pharmacokinetics | Choroid Plexus - blood supply | ATP-Binding Cassette Transporters - genetics | Ochratoxins - administration & dosage | Cell Membrane - metabolism | Cerebral Cortex - drug effects | Capillaries - metabolism | Fluorobenzenes - metabolism | Tetrahydroisoquinolines - pharmacology | Organic Cation Transport Proteins - metabolism | Pravastatin - metabolism | Liver - metabolism | Rosuvastatin Calcium | Sulfonamides - pharmacokinetics | Blood-Brain Barrier - metabolism | Mice, Knockout | Brain - drug effects | Taurocholic Acid - administration & dosage | Pravastatin - administration & dosage | Enkephalin, D-Penicillamine (2,5)- - administration & dosage | Pyrimidines - pharmacokinetics | Mice | Kinetics | Organic Cation Transport Proteins - genetics | Pravastatin - pharmacokinetics | Sulfonamides - administration & dosage | Quinolines - blood | Digoxin - metabolism | Taurocholic Acid - metabolism | Choroid Plexus - metabolism | Taurocholic Acid - blood | Ochratoxins - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Ochratoxins - metabolism | Cerebral Cortex - metabolism | Organic Anion Transporters - metabolism | Brain - blood supply | Sulfonamides - blood | Organic Anion Transporters - genetics | Transfection | Fluorobenzenes - blood | Enkephalin, D-Penicillamine (2,5)- - pharmacokinetics | Recombinant Proteins - metabolism | Cell Line | Pyrimidines - administration & dosage | Mice, Inbred C57BL | Recombinant Proteins - genetics | Blood-Brain Barrier - drug effects | Digoxin - pharmacokinetics | Quinolines - metabolism | Taurocholic Acid - pharmacokinetics | Liver - blood supply | Pharmaceutical Preparations - metabolism | Animals | Digoxin - administration & dosage | Enkephalin, D-Penicillamine (2,5)- - metabolism | Acridines - pharmacology | Sulfonamides - metabolism
Journal Article